Biogen, Inc. (BIIB)
253.41
+2.93
(+1.17%)
USD |
NASDAQ |
Nov 13, 16:00
253.41
0.00 (0.00%)
After-Hours: 19:59
Biogen Enterprise Value : 43.52B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 43.52B |
| November 11, 2026 | 43.95B |
| November 10, 2026 | 43.93B |
| November 09, 2026 | 44.17B |
| November 06, 2026 | 43.20B |
| November 05, 2026 | 42.55B |
| November 04, 2026 | 44.11B |
| November 03, 2026 | 43.29B |
| November 02, 2026 | 43.30B |
| October 30, 2026 | 43.98B |
| October 29, 2026 | 43.40B |
| October 28, 2026 | 42.57B |
| October 27, 2026 | 43.85B |
| October 26, 2026 | 43.78B |
| October 23, 2026 | 43.55B |
| October 22, 2026 | 44.01B |
| October 21, 2026 | 42.11B |
| October 20, 2026 | 42.43B |
| October 19, 2026 | 41.01B |
| October 16, 2026 | 40.88B |
| October 15, 2026 | 41.28B |
| October 14, 2026 | 40.91B |
| October 13, 2026 | 40.33B |
| October 12, 2026 | 40.40B |
| October 09, 2026 | 39.86B |
| Date | Value |
|---|---|
| October 08, 2026 | 38.78B |
| October 07, 2026 | 39.33B |
| October 06, 2026 | 39.44B |
| October 05, 2026 | 39.54B |
| October 02, 2026 | 39.00B |
| October 01, 2026 | 39.43B |
| September 30, 2026 | 39.88B |
| September 29, 2026 | 40.61B |
| September 28, 2026 | 40.85B |
| September 25, 2026 | 40.69B |
| September 24, 2026 | 40.50B |
| September 23, 2026 | 40.68B |
| September 22, 2026 | 40.36B |
| September 21, 2026 | 39.43B |
| September 18, 2026 | 38.90B |
| September 17, 2026 | 39.42B |
| September 16, 2026 | 38.97B |
| September 15, 2026 | 39.00B |
| September 14, 2026 | 39.17B |
| September 11, 2026 | 39.14B |
| September 10, 2026 | 38.89B |
| September 09, 2026 | 38.19B |
| September 08, 2026 | 38.46B |
| September 04, 2026 | 39.69B |
| September 03, 2026 | 40.23B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AbbVie, Inc. | 590.62B |
| Gilead Sciences, Inc. | 226.62B |
| Amgen, Inc. | 293.45B |
| Regeneron Pharmaceuticals, Inc. | 91.75B |
| Eli Lilly & Co. | 1.388T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -20.60M |
| Revenue (Quarterly) | 2.691B |
| Total Expenses (Quarterly) | 2.712B |
| EPS Diluted (Quarterly) | -0.1394 |
| Gross Profit Margin (Quarterly) | 63.23% |
| Profit Margin (Quarterly) | -0.77% |
| Earnings Yield | 0.92% |
| Operating Earnings Yield | 4.57% |
| Normalized Earnings Yield | 3.043 |